Evidence map›Paper›PMID 33125736›Full record

ArticleMuscle & nerve2021

(-)-Epicatechin induces mitochondrial biogenesis and markers of muscle regeneration in adults with Becker muscular dystrophy.

Craig M McDonald, Israel Ramirez-Sanchez, Björn Oskarsson, Nanette Joyce, Candace Aguilar, Alina Nicorici, Jonathan Dayan, Erica Goude, R Ted Abresch, Francisco Villarreal and 5 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Muscle & nerve, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06631820 (The Effect of the Nutraceutical), which is not on this map. Cited by 36 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06631820 narecruitingnot on this mapstarted 2025, after this paper: background citation

The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD: a Pilot Study (EPIC-CKD)

TypeinterventionalSponsorKarolinska InstitutetRan2025 to 2026Enrolled10ConditionsChronic Kidney Disease(CKD), Myosteatosis, Mitochondrial Dysfunction, Muscle FunctionArmsEpicatechin extract
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Response of VOPhysiological reports · 2025
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Myokines and mitochondrial function in cardiometabolic diseases.Journal of physiology and biochemistry · 2026
    Review
  8. Article
  9. Exercise pills for cardiometabolic health cannot mimic the exercise milieu.Trends in endocrinology and metabolism: TEM · 2026
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Frontiers in pharmacology · 2025
    Review
  17. Review
  18. Investigation of AlgerianAntioxidants (Basel, Switzerland) · 2024
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Craig M McDonaldDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0002-8779-3220
Israel Ramirez-SanchezDivision of Cardiology, Department of Internal Medicine, University of California at San Diego, San Diego, California, USA.
Björn OskarssonDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.ORCID 0000-0002-1725-9866
Nanette JoyceDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
Candace AguilarDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
Alina NicoriciDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
Jonathan DayanDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
Erica GoudeDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
R Ted AbreschDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.
Francisco VillarrealDivision of Cardiology, Department of Internal Medicine, University of California at San Diego, San Diego, California, USA.ORCID 0000-0002-3251-4909
Guillermo CeballosEscuela Superior de Medicina, Seccion de Posgrado e Investigacion, del Instituto Politécnico Nacional, Mexico City, Mexico.ORCID 0000-0003-2155-3934
Guy PerkinsDivision of Cardiology, Department of Internal Medicine, University of California at San Diego, San Diego, California, USA.
Sundeep DugarEpirium Bio, Inc (formerly Cardero Therapeutics, Inc), San Diego, California, USA.
George SchreinerEpirium Bio, Inc (formerly Cardero Therapeutics, Inc), San Diego, California, USA.
Erik K HenricsonDepartment of Physical Medicine and Rehabilitation, University of California Davis School of Medicine, Sacramento, California, USA.ORCID 0000-0002-7511-6441
University of California, Davis · USUniversity of San Diego · USIo Therapeutics (United States) · USInstituto Politécnico Nacional · MXJacksonville College · US

Funding

National Center for Microscopy and Imaging Research: A BRAIN Technology Integration and Dissemination ResourceU24NS120055 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELLISMAN, MARK H · 2021 to 2025
$5.4M
The National Center for Microscopy and Imaging Research, a Community-wide Scientific ResourceR24GM137200 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ELLISMAN, MARK H · 2020 to 2022
$3.0M
NIGMS NIH HHS R24 GM137200NINDS NIH HHS U24 NS120055
6 · The paper itself

Abstract

introductionWe conducted an open-label study to examine the effects of the flavonoid (-)-epicatechin in seven ambulatory adult patients with Becker muscular dystrophy (BMD).

methodsSeven participants received (-)-epicatechin 50 mg twice per day for 8 weeks. Pre- and postprocedures included biceps brachii biopsy to assess muscle structure and growth-relevant endpoints by western blotting, mitochondria volume measurement, and cristae abundance by electron microscopy, graded exercise testing, and muscle strength and function tests.

resultsWestern blotting showed significantly increased levels of enzymes modulating cellular bioenergetics (liver kinase B1 and 5'-adenosine monophosphate-activated protein kinase). Peroxisome proliferator-activated receptor gamma coactivator-1alpha, a transcriptional coactivator of genes involved in mitochondrial biogenesis and cristae-associated mitofilin levels, increased as did cristae abundance. Muscle and plasma follistatin increased significantly while myostatin decreased. Markers of skeletal muscle regeneration myogenin, myogenic regulatory factor-5, myoblast determination protein 1, myocyte enhancer factor-2, and structure-associated proteins, including dysferlin, utrophin, and intracellular creatine kinase, also increased. Exercise testing demonstrated decreased heart rate, maximal oxygen consumption per kilogram, and plasma lactate levels at defined workloads. Tissue saturation index improved in resting and postexercise states. DISCUSSION: (-)-Epicatechin, an exercise mimetic, appears to have short-term positive effects on tissue biomarkers indicative of mitochondrial biogenesis and muscle regeneration, and produced improvements in graded exercise testing parameters in patients with BMD.

Indexed as

AdultBiopsyBlotting, WesternCatechinCreatine KinaseDysferlinExercise TestFollistatinHeart RateHumansLactic AcidMaleMEF2 Transcription FactorsMicroscopy, ElectronMiddle AgedMitochondriaCatechinCreatine KinaseDysferlinFollistatinIMMT protein, humanLactic AcidMEF2 Transcription FactorsMitochondrial ProteinsMuscle ProteinsMyoD1 myogenic differentiation proteinMyoD ProteinMyogenic Regulatory Factor 5MyogeninMyostatinPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPARGC1A protein, humanUtrophinaerobic exercise, Becker muscular dystrophy, epicatechin, mitochondrial biogenesis follistatin

Identifiers

PMID33125736
PMCPMC7898288
OpenAlexW3096910945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.